Five times in a row! Medicilon was shortlisted in the “2022 China CXO Enterprises Top 20 List”
On June 27, the 2022 China Pharmaceutical Industry Top 100 Series List was released. Shanghai Medicilon Inc. was once again shortlisted in the “China CXO Enterprises Top 20 List”.
Being on the list for five consecutive times is a high affirmation and praise from industry authorities for the comprehensive strength of Medicilon’s one-stop biopharmaceutical preclinical R&D service platform. It is also the recognition and encouragement of the sustainable development of Medicilon in the future!
“China’s Top 100 Pharmaceutical Industry List Series” is initiated and hosted by Menet.com.cn, a leading platform for China’s pharmaceutical and health information. It aims to set a benchmark for china pharmaceutical industry enterprises to enhance their comprehensive strength and expand brand effectiveness, demonstrate the excellence of the pharmaceutical brand industry, and guide the steady, rapid and sustainable development of the pharmaceutical and health industry. This list is selected from the two most important factors, innovation and professional promotion. The selection process has received high attention and active participation from professional research institutions, industry experts and colleagues, which shows its professionalism and authoritative.
